Effect of a radiolabel biochemical nature on tumor-targeting properties of EpCAM-binding engineered scaffold protein DARPin Ec1

Sergey M. Deyev, Anzhelika Vorobyeva, Alexey Schulga, Ayman Abouzayed, Tyran Günther, Javad Garousi, Elena Konovalova, Haozhong Ding, Torbjörn Gräslund, Anna Orlova, Vladimir Tolmachev

Research output: Contribution to journalArticle

Abstract

Radionuclide-based imaging of molecular therapeutic targets might facilitate stratifying patients for specific biotherapeutics. New type of imaging probes, based on designed ankyrin repeat proteins (DARPins), have demonstrated excellent contrast of imaging of human epidermal growth factor type 2 (HER2) expression in preclinical models. We hypothesized that labeling approaches, which result in lipophilic radiometabolites (non-residualizing labels), would provide the best imaging contrast for DARPins that internalize slowly after binding to cancer cells. The hypothesis was tested using DARPin Ec1 that binds to epithelial cell adhesion molecule (EpCAM). EpCAM is a promising therapeutic target. Ec1 was labeled with 125I using two methods to obtain the non-residualizing labels, while residualizing labels were obtained by labeling it with 99mTc. All labeled Ec1 variants preserved target specificity and picomolar binding affinity to EpCAM-expressing pancreatic adenocarcinoma BxPC-3 cells. In murine models, all the variants provided similar tumor uptake. However, 125I-PIB-H6-Ec1 had noticeably lower retention in normal tissues, which provided appreciably higher tumor-to-organ ratios. Furthermore, 125I-PIB-H6-Ec1 demonstrated the highest imaging contrast in preclinical models than any other EpCAM-imaging agent tested so far. In conclusion, DARPin Ec1 in combination with a non-residualizing label is a promising probe for imaging EpCAM expression a few hours after injection.

Original languageEnglish
Pages (from-to)216-225
Number of pages10
JournalInternational Journal of Biological Macromolecules
Volume145
DOIs
Publication statusPublished - 15 Feb 2020

Fingerprint

Ankyrin Repeat
Cell adhesion
Cell Adhesion Molecules
Scaffolds (biology)
Scaffolds
Tumors
Proteins
Imaging techniques
Molecules
Labels
Neoplasms
Labeling
Epidermal Growth Factor
Radionuclide Imaging
Adenocarcinoma
Epithelial Cells
Epithelial Cell Adhesion Molecule
Targeting
Adhesion
Imaging

Keywords

  • Biodistribution
  • Designed ankyrin repeat protein
  • EpCAM
  • Labeling
  • Structure-property relationship

ASJC Scopus subject areas

  • Structural Biology
  • Biochemistry
  • Molecular Biology
  • Economics and Econometrics
  • Energy(all)

Cite this

Effect of a radiolabel biochemical nature on tumor-targeting properties of EpCAM-binding engineered scaffold protein DARPin Ec1. / Deyev, Sergey M.; Vorobyeva, Anzhelika; Schulga, Alexey; Abouzayed, Ayman; Günther, Tyran; Garousi, Javad; Konovalova, Elena; Ding, Haozhong; Gräslund, Torbjörn; Orlova, Anna; Tolmachev, Vladimir.

In: International Journal of Biological Macromolecules, Vol. 145, 15.02.2020, p. 216-225.

Research output: Contribution to journalArticle

Deyev, SM, Vorobyeva, A, Schulga, A, Abouzayed, A, Günther, T, Garousi, J, Konovalova, E, Ding, H, Gräslund, T, Orlova, A & Tolmachev, V 2020, 'Effect of a radiolabel biochemical nature on tumor-targeting properties of EpCAM-binding engineered scaffold protein DARPin Ec1', International Journal of Biological Macromolecules, vol. 145, pp. 216-225. https://doi.org/10.1016/j.ijbiomac.2019.12.147
Deyev, Sergey M. ; Vorobyeva, Anzhelika ; Schulga, Alexey ; Abouzayed, Ayman ; Günther, Tyran ; Garousi, Javad ; Konovalova, Elena ; Ding, Haozhong ; Gräslund, Torbjörn ; Orlova, Anna ; Tolmachev, Vladimir. / Effect of a radiolabel biochemical nature on tumor-targeting properties of EpCAM-binding engineered scaffold protein DARPin Ec1. In: International Journal of Biological Macromolecules. 2020 ; Vol. 145. pp. 216-225.
@article{546fe7adb5e8452bbd983bb5971763cb,
title = "Effect of a radiolabel biochemical nature on tumor-targeting properties of EpCAM-binding engineered scaffold protein DARPin Ec1",
abstract = "Radionuclide-based imaging of molecular therapeutic targets might facilitate stratifying patients for specific biotherapeutics. New type of imaging probes, based on designed ankyrin repeat proteins (DARPins), have demonstrated excellent contrast of imaging of human epidermal growth factor type 2 (HER2) expression in preclinical models. We hypothesized that labeling approaches, which result in lipophilic radiometabolites (non-residualizing labels), would provide the best imaging contrast for DARPins that internalize slowly after binding to cancer cells. The hypothesis was tested using DARPin Ec1 that binds to epithelial cell adhesion molecule (EpCAM). EpCAM is a promising therapeutic target. Ec1 was labeled with 125I using two methods to obtain the non-residualizing labels, while residualizing labels were obtained by labeling it with 99mTc. All labeled Ec1 variants preserved target specificity and picomolar binding affinity to EpCAM-expressing pancreatic adenocarcinoma BxPC-3 cells. In murine models, all the variants provided similar tumor uptake. However, 125I-PIB-H6-Ec1 had noticeably lower retention in normal tissues, which provided appreciably higher tumor-to-organ ratios. Furthermore, 125I-PIB-H6-Ec1 demonstrated the highest imaging contrast in preclinical models than any other EpCAM-imaging agent tested so far. In conclusion, DARPin Ec1 in combination with a non-residualizing label is a promising probe for imaging EpCAM expression a few hours after injection.",
keywords = "Biodistribution, Designed ankyrin repeat protein, EpCAM, Labeling, Structure-property relationship",
author = "Deyev, {Sergey M.} and Anzhelika Vorobyeva and Alexey Schulga and Ayman Abouzayed and Tyran G{\"u}nther and Javad Garousi and Elena Konovalova and Haozhong Ding and Torbj{\"o}rn Gr{\"a}slund and Anna Orlova and Vladimir Tolmachev",
year = "2020",
month = "2",
day = "15",
doi = "10.1016/j.ijbiomac.2019.12.147",
language = "English",
volume = "145",
pages = "216--225",
journal = "International Journal of Biological Macromolecules",
issn = "0141-8130",
publisher = "Elsevier",

}

TY - JOUR

T1 - Effect of a radiolabel biochemical nature on tumor-targeting properties of EpCAM-binding engineered scaffold protein DARPin Ec1

AU - Deyev, Sergey M.

AU - Vorobyeva, Anzhelika

AU - Schulga, Alexey

AU - Abouzayed, Ayman

AU - Günther, Tyran

AU - Garousi, Javad

AU - Konovalova, Elena

AU - Ding, Haozhong

AU - Gräslund, Torbjörn

AU - Orlova, Anna

AU - Tolmachev, Vladimir

PY - 2020/2/15

Y1 - 2020/2/15

N2 - Radionuclide-based imaging of molecular therapeutic targets might facilitate stratifying patients for specific biotherapeutics. New type of imaging probes, based on designed ankyrin repeat proteins (DARPins), have demonstrated excellent contrast of imaging of human epidermal growth factor type 2 (HER2) expression in preclinical models. We hypothesized that labeling approaches, which result in lipophilic radiometabolites (non-residualizing labels), would provide the best imaging contrast for DARPins that internalize slowly after binding to cancer cells. The hypothesis was tested using DARPin Ec1 that binds to epithelial cell adhesion molecule (EpCAM). EpCAM is a promising therapeutic target. Ec1 was labeled with 125I using two methods to obtain the non-residualizing labels, while residualizing labels were obtained by labeling it with 99mTc. All labeled Ec1 variants preserved target specificity and picomolar binding affinity to EpCAM-expressing pancreatic adenocarcinoma BxPC-3 cells. In murine models, all the variants provided similar tumor uptake. However, 125I-PIB-H6-Ec1 had noticeably lower retention in normal tissues, which provided appreciably higher tumor-to-organ ratios. Furthermore, 125I-PIB-H6-Ec1 demonstrated the highest imaging contrast in preclinical models than any other EpCAM-imaging agent tested so far. In conclusion, DARPin Ec1 in combination with a non-residualizing label is a promising probe for imaging EpCAM expression a few hours after injection.

AB - Radionuclide-based imaging of molecular therapeutic targets might facilitate stratifying patients for specific biotherapeutics. New type of imaging probes, based on designed ankyrin repeat proteins (DARPins), have demonstrated excellent contrast of imaging of human epidermal growth factor type 2 (HER2) expression in preclinical models. We hypothesized that labeling approaches, which result in lipophilic radiometabolites (non-residualizing labels), would provide the best imaging contrast for DARPins that internalize slowly after binding to cancer cells. The hypothesis was tested using DARPin Ec1 that binds to epithelial cell adhesion molecule (EpCAM). EpCAM is a promising therapeutic target. Ec1 was labeled with 125I using two methods to obtain the non-residualizing labels, while residualizing labels were obtained by labeling it with 99mTc. All labeled Ec1 variants preserved target specificity and picomolar binding affinity to EpCAM-expressing pancreatic adenocarcinoma BxPC-3 cells. In murine models, all the variants provided similar tumor uptake. However, 125I-PIB-H6-Ec1 had noticeably lower retention in normal tissues, which provided appreciably higher tumor-to-organ ratios. Furthermore, 125I-PIB-H6-Ec1 demonstrated the highest imaging contrast in preclinical models than any other EpCAM-imaging agent tested so far. In conclusion, DARPin Ec1 in combination with a non-residualizing label is a promising probe for imaging EpCAM expression a few hours after injection.

KW - Biodistribution

KW - Designed ankyrin repeat protein

KW - EpCAM

KW - Labeling

KW - Structure-property relationship

UR - http://www.scopus.com/inward/record.url?scp=85076990349&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076990349&partnerID=8YFLogxK

U2 - 10.1016/j.ijbiomac.2019.12.147

DO - 10.1016/j.ijbiomac.2019.12.147

M3 - Article

C2 - 31863835

AN - SCOPUS:85076990349

VL - 145

SP - 216

EP - 225

JO - International Journal of Biological Macromolecules

JF - International Journal of Biological Macromolecules

SN - 0141-8130

ER -